Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer

被引:24
|
作者
Behrouzi, Roya [1 ]
Ryan, Neil A. J. [2 ]
Barr, Chloe E. [3 ]
Derbyshire, Abigail E. [3 ]
Wan, Y. Louise [2 ]
Maskell, Zoe [2 ]
Stocking, Katie [4 ]
Pemberton, Philip W. [5 ]
Bolton, James [6 ]
McVey, Rhona J. [6 ]
Crosbie, Emma J. [2 ,3 ]
机构
[1] Manchester Univ NHS Fdn Trust, Dept Med, Manchester M13 9WL, Lancs, England
[2] Univ Manchester, St Marys Hosp, Fac Biol Med & Hlth, Div Canc Sci, Manchester M13 9WL, Lancs, England
[3] Manchester Univ NHS Fdn Trust, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Dept Obstet & Gynaecol, Manchester M13 9WL, Lancs, England
[4] Univ Manchester, Ctr Biostat, Hlth Serv Res & Primary Care, Div Populat Hlth, Manchester M13 9PL, Lancs, England
[5] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Dept Clin Biochem, Manchester M13 9WL, Lancs, England
[6] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Dept Pathol, Manchester M13 9WL, Lancs, England
关键词
HE4; endometrial cancer; atypical hyperplasia; biomarker; therapy; response; levonorgestrel-releasing intrauterine system; LNG-IUS; PROGNOSTIC MARKER; LONG-TERM; ADENOCARCINOMA; PROGESTIN; THERAPY; WOMEN; METAANALYSIS; MULTICENTER; MANAGEMENT; BIOMARKER;
D O I
10.3390/cancers12020276
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE4 expression could predict response to LNG-IUS therapy. Patients with AH or presumed Stage I EEC had serum and endometrial samples taken at baseline and at 3-month intervals over 12 months post-insertion of LNG-IUS. 74 patients were recruited and baseline demographics recorded. Of 57 patients for whom response was histologically determinable, 39 (68%) were responders and 18 (32%) non-responders. Mean baseline serum HE4 was significantly lower in responders (62.1 +/- 1.1 pM, 95% confidence interval (CI) 52.7-73.2), compared to non-responders (125.6 +/- 1.3 pM, 95% CI 74.5-211.7, p = 0.014), including when considering age, BMI, menopausal status, smoking status, and histological grade as covariables (p = 0.005). Baseline tissue HE4 expression was not significantly different in responders compared to non-responders (p = 0.999). Responders showed a significant mean reduction (-9.8 +/- 3.4%, 95% CI -16.7 to -2.8%, p = 0.008) in serum HE4 between baseline and 3 months (p = 0.008), whereas non-responders showed no significant change (p = 0.676). Neither responders nor non-responders showed a significant percentage change in serum HE4 from baseline beyond 3 months (p > 0.05). Change in serum HE4 between baseline and 3 and 6 months and tissue HE4 tissue expression between baseline and 3, 6, and 12 months was not significantly different in responders compared to non-responders (p > 0.05). This study suggests that baseline serum HE4, but not baseline tissue HE4 expression, is independently predictive of response to the LNG-IUS and could be used to guide management decisions.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study
    Barr, Chloe E.
    Sergeant, Jamie C.
    Agnew, Heather J.
    Bolton, James
    McVey, Rhona J.
    Crosbie, Emma J.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2023, 130 (08) : 941 - 948
  • [2] PROGNOSTIC VALUE OF SERUM HE4 LEVEL IN ENDOMETRIAL CANCER
    Rajadevan, N.
    McNally, O.
    Neesham, D.
    Richards, A.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 1169 - 1169
  • [3] The role of novel serum biomarker HE4 in endometrial cancer
    Angioli, R.
    Capriglione, S.
    Plotti, F.
    Terranova, C.
    Oronzi, I.
    Cafa, E.
    Montone, E.
    Gennari, P.
    Linciano, F.
    Benedetti-Panici, P.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 : S148 - S148
  • [4] Utility of Serum HE4 in Diagnosis and Prognosis of Endometrial Cancer
    O'Toole, S. A.
    Rizmee, S.
    Norris, L.
    Cullen, M.
    Zainulabdin, A.
    Long, J. C.
    Martin, F.
    Cooney, A.
    Ripollone, S.
    Ibrahim, N.
    Abu Saadeh, F.
    Kamran, W.
    Murphy, C.
    D'Arcy, T.
    Gleeson, N. C.
    O'Leary, J. J.
    [J]. JOURNAL OF PATHOLOGY, 2015, 237 : S15 - S15
  • [5] Role of serum HE4 in studying ovarian cancer progression and response to therapy with ARCHITECT HE4 assay
    Kenney, D.
    Radwan, R.
    Zhu, L.
    Burkhart, B.
    Glover, C.
    Vasko, A.
    Young, J.
    Acon, B.
    Polkowski, J.
    Raju, S.
    Falcone, K.
    Li, Z.
    Dickson, D.
    Simamora, R.
    Kettlety, T.
    Barnes, G.
    [J]. CANCER RESEARCH, 2010, 70
  • [6] Role of serum HE4 in studying ovarian cancer progression and response to therapy with ARCHITECT HE4 assay
    Kenney, D.
    Radwan, R.
    Zhu, L.
    Burkhart, B.
    Glover, C.
    Vasko, A.
    Young, J.
    Acon, B.
    Polkowski, J.
    Raju, S.
    Falcone, K.
    Li, Z.
    Dickson, D.
    Simamora, R.
    Kettlety, T.
    Barnes, G.
    [J]. CANCER RESEARCH, 2010, 70
  • [7] Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer
    Hirata, Toru
    Kondo, Eiji
    Magawa, Shoichi
    Kubo-Kaneda, Michiko
    Nii, Masafumi
    Yoshida, Kenta
    Maezawa, Tadashi
    Tabata, Tsutomu
    Ikeda, Tomoaki
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (12) : 3219 - 3225
  • [8] Expression of HE4 in Endometrial Cancer and Its Clinical Significance
    Li, Xiao
    Gao, Yiping
    Tan, Mingzi
    Zhuang, Huiyu
    Gao, Jian
    Hu, Zhenhua
    Wang, Huimin
    Zhu, Liancheng
    Liu, Juanjuan
    Lin, Bei
    [J]. BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [9] HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review
    Karlsen, Nikoline S.
    Karlsen, Mona A.
    Hogdall, Claus K.
    Hogdall, Estrid V. S.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (11) : 2285 - 2295
  • [10] Combination of serum CST1 and HE4 for early diagnosis of endometrial cancer
    Zhong, Wenhui
    Liu, Yunliang
    Zhang, Liangming
    Zhuang, Wanzhen
    Chen, Jianlin
    Huang, Zhixin
    Zheng, Yue
    Huang, Yi
    [J]. PEERJ, 2023, 11